EUCTR2005-005742-39-LT进行中（未招募）不适用
A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg (given as 2 injections of 60 mg on Day 1 and repeated on Day 2) in patients with advanced prostate cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically proven adenocarcinoma of the prostate
- •- Androgen deprivation therapy suitable (advanced prostate cancer i.e. with local invasion or/and metastasis)
- •- Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Liver or renal function tests (ASAT/SGOT, ALAT/SGPT, total bilirubin, creatinine) exceeding twice the upper limit of the normal range, unless the elevation is attributed to hepatic metastasis
- •- Any contraindication to the use of Teverelix LA
- •- Life expectancy of less than 1 year
- •- Baseline testosterone value below 2.31 ng/ml
- •- Bilateral orchidectomy
- •- Pre-existing hormone therapy or planned concomitant use of androgen deprivation therapy with any agent other than the investigational drug
- •- Neurological, psychiatric disease, drug or alcohol abuse which could interfere with the subject’s proper compliance
- •- Evidence of concurrent malignancy
- •- Exposure to another investigational agent within the last month
- •- Lack of ability or willingness to give informed consent
- •- Anticipated non-availability for study visits/ procedures
研究者
相似试验
进行中（未招募）
不适用
A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg in patients with advanced prostate cancerEUCTR2005-002100-42-LTArdana Bioscience Ltd8
招募中
1 期
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patientsCTIS2023-505241-10-00Medibiofarma S.L.10
进行中（未招募）
2 期
An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanomaCancer - Malignant melanomaMelanomaACTRN12613000737730Melanoma Institute Australia35
进行中（未招募）
1 期
A PRX302 (protein) injection directly into the prostate to treat prostate cancer that has not spread beyond the prostateProstate cancerEUCTR2014-003386-22-GBSophiris Bio Corp20
进行中（未招募）
1 期
An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcomaEUCTR2017-002877-20-DKytix Biopharma AS6